Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 7/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952398 | 1.00 | MAP3K12 (0.38) | MAP3K12MTORPIK3CAMGLLTNF | |
| SCHEMBL26917129 | 0.80 | MAP3K12 (0.35) | MAP3K12 | |
| SCHEMBL21382388 | 0.79 | MGLL (0.36) | MGLL | |
| SCHEMBL25191949 | 0.78 | PIK3CD (0.45) | MGLLPIK3CD | |
| SCHEMBL17609497 | 0.78 | MGLL (0.35) | MGLL | |
| SCHEMBL3518343 | 0.76 | MAP3K12 (0.39) | MAP3K12PIK3CA | |
| SCHEMBL25346943 | 0.75 | PDGFRB (0.40) | — | |
| SCHEMBL9902936 | 0.74 | MGLL (0.35) | MGLL | |
| SCHEMBL29601287 | 0.74 | GLA (0.45) | MAP3K12MTORPIK3CATNFPIK3CD | |
| SCHEMBL21031807 | 0.74 | GLA (0.45) | MAP3K12MTORPIK3CATNFPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| US-9062046-B2 | Substituted imidazoquinoline derivatives as kinase inhibitors | Piramal Enterprises Limited (IN) | 2015-06-23 | — | — | US | disclosed |
| WO-2014080241-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2014-05-30 | — | — | WO | disclosed |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | disclosed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | disclosed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK4, MAP3K1 | MAP3K12 16/4885MTOR 102/4885PIK3CA 72/4885 |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | FLT4, CDK4, CDK2 | MAP3K12 41/4885MTOR 220/4885PIK3CA 154/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | MAP3K12 2160/4885MTOR 729/4885PIK3CA 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.